Actively Recruiting
Evaluating Safety and Preliminary Effects of Multiple Intravaginal Doses of GenSci142 Compared to Clindamycin Cream for Bacterial Vaginosis in Women Aged 18 to 50
Led by Changchun GeneScience Pharmaceutical Co., Ltd. · Updated on 2026-10-15
42
Participants Needed
9
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of multiple doses of GenSci142 administered intravaginally in women aged 18 to 50 years diagnosed with bacterial vaginosis BV, including those with mild aerobic vaginitis. This randomized, multicenter, open-label Phase Ib clinical trial aims to provide foundational data to support further clinical development of this treatment. Approximately 30 to 42 participants will be randomized in a 21 ratio to either the GenSci142 treatment group or a control group receiving clindamycin phosphate vaginal cream. Participants will receive either multiple intravaginal doses of GenSci142 or 2% clindamycin phosphate vaginal cream applied once daily for 7 days. The study includes a screening period of about 3 days, a 7-day treatment period, and a 90-day efficacy evaluation period, during which participants will attend a total of seven scheduled visits. The trial is open-label, meaning both participants and researchers know which treatment is administered. During the study, participants will undergo assessments including clinical evaluations for cure and recurrence of BV using Amsel criteria and Nugent score, measurement of drug concentrations in blood, and monitoring for treatment-emergent adverse events up to 30 days from the first dose. Additional follow-up will assess anti-drug antibodies and recurrence rates up to 90 days. Participants are expected to abstain from sexual intercourse around dosing and visit times and follow specific vaginal product restrictions to ensure accurate study results.
CONDITIONS
Brief Title
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
Research Team
L
Liao Qinping
Z
Zhang Lei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here